Idorsia to collaborate with two leading academic medical centers to launch IMPACT-HTN – a US initiative to transform care for patients with difficult-to-control hypertension
(IDIA) Allschwil, Switzerland & Radnor, Philadelphia – September 5, 2025
Idorsia Ltd (SIX: IDIA) announces a first-of-its-kind initiative with the Stanford Hypertension Center and Duke Heart Center to launch IMPACT-HTN, a new three-phase program to transform and modernize the management of difficult-to-control hypertension. Patients requiring multiple medications for difficult-to-control hypertension face increasing challenges with care coordination, evaluation of underlying causes, and worsening outcomes. The initiative, led by Dr. Vivek Bhalla of the Stanford University School of Medicine and Dr. Sreekanth Vemulapalli of Duke University School of Medicine, is expected to generate real-world evidence, standardize clinical decision-making and deliver scalable tools that leverage AI technology to help identify patients with difficult-to-control hypertension who may benefit from innovative therapies that utilize new pathways, including Idorsia's once-daily TRYVIO™ (aprocitentan), the first syst
Related Questions
What measurable milestones (e.g., patient enrollment, real‑world evidence generation, AI tool deployment) are tied to the three‑phase IMPACT‑HTN program, and how might they influence long‑term market share in the difficult‑to‑control hypertension segment?
How will the collaboration with Stanford and Duke and the launch of IMPACT-HTN affect Idorsia's near‑term revenue outlook and stock valuation?
What is the expected timeline for regulatory approval and commercial rollout of TRYVIO™ (aprocitentan) in the U.S., and how does it compare to competing hypertension therapies?